Moreover, based on high density of transmembrane NK1Rs on human cancer cells, new therapeutic approaches involve the use of radiolabelled NK1R ligands in targeted radionuclide tumour therapy [2,15,16,17]. Here, TACR1 is linked to neoplasm.